Home » Posts tagged 'data'
Tag Archives: data
#ECR Minerals – Collaboration Agreement with James Cook University on Rare Earth Elements at the Lolworth Project
ECR Minerals PLC (AIM: ECR), the gold exploration and development company focused on Australia, is pleased to announce that it has entered into a collaboration agreement with James Cook University (“JCU”) in Queensland, a leading institution in science and engineering research, to further explore the potential for rare earth elements (“REE”) within the Company’s Lolworth Project area in Queensland (the “Lolworth Project”).
Following approval of funding for the project by the Trailblazer Steering Committee, the collaboration will see JCU recruit post-doctoral researchers and PhD students to form a dedicated team. This dedicated team will focus on analysing and interpreting the mineral data from the Lolworth Project area to enhance the understanding of its REE potential.
Under the terms of the collaboration agreement, all data generated through this collaboration will be shared with ECR, further strengthening the Company’s technical insights into the region. While ECR is pleased to support JCU in this important research initiative, the pace of the Company’s broader technical development across the wider Lolworth Project area will continue to be driven by its own technical team and exploration priorities.
James Cook University is a public university in North Queensland, Australia. The second oldest university in Queensland, JCU is a teaching and research institution with its main campuses located in Cairns and Townsville, and one in Singapore. JCU is ranked in the world’s top 300 universities by the Times Higher Education World University Rankings 2022 and also has study centres in Mount Isa, Mackay, Thursday Island and Rockhampton.
Mike Whitlow, ECR’s Managing Director, said: “We are thrilled to see further validation of our projects in Queensland, in particular the Lolworth Project, through this exciting collaboration with James Cook University. This partnership, which is fully funded by JCU, not only underscores the growing interest in the Lolworth Project region, but also expands our technical understanding of a fast-emerging area of interest. Combined with our existing collaboration with the Geological Survey of Queensland, this initiative places ECR in a stronger position to potentially unlock the Lolworth Project’s REE potential and create significant shareholder value.”
FOR FURTHER INFORMATION, PLEASE CONTACT:
ECR Minerals Plc |
Tel: +44 (0) 1738 317 693 |
||
Nick Tulloch, Chairman Andrew Scott, Director |
|||
Email: info@ecrminerals.com |
|||
Website: www.ecrminerals.com |
|||
Allenby Capital Limited |
|
Tel: +44 (0) 3328 5656 |
|
Nominated Adviser Nick Naylor / Alex Brearley / Vivek Bhardwaj |
|
||
Axis Capital Markets Limited |
Tel: +44 (0) 203 026 0320 |
||
Broker |
|||
Ben Tadd / Lewis Jones |
|||
|
|||
SI Capital Ltd |
Tel: +44 (0) 1483 413500 |
||
Broker |
|||
Nick Emerson
|
|||
Brand Communications |
Tel: +44 (0) 7976 431608 |
||
Public & Investor Relations |
|||
Alan Green |
ABOUT ECR MINERALS PLC
ECR Minerals is a mineral exploration and development company. ECR’s wholly owned Australian subsidiary Mercator Gold Australia Pty Ltd (“MGA”) has 100% ownership of the Bailieston and Creswick gold projects in central Victoria, Australia, has six licence applications outstanding which includes one licence application lodged in eastern Victoria (Tambo gold project).
ECR also owns 100% of an Australian subsidiary LUX Exploration Pty Ltd (“LUX”) which has three approved exploration permits covering 946 km2 over a relatively unexplored area in Lolworth Range, Queensland, Australia. The Company has also submitted a license application at Kondaparinga which is approximately 120km2 in area and located within the Hodgkinson Gold Province, 80km NW of Mareeba, North Queensland.
Following the sale of the Avoca, Moormbool and Timor gold projects in Victoria, Australia to Fosterville South Exploration Ltd (TSX-V: FSX) and the subsequent spin-out of the Avoca and Timor projects to Leviathan Gold Ltd (TSX-V: LVX), MGA has the right to receive up to A$2 million in payments subject to future resource estimation or production from projects sold to Fosterville South Exploration Limited.
MGA also has approximately A$75 million of unutilised tax losses incurred during previous operations.
#POLB Poolbeg Pharma – GMP manufacturing contract signed
Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces an update on its lead asset, POLB 001, a small molecule immunomodulator which aims to address a significant unmet need in severe influenza. The Company has signed a contract for GMP manufacturing, ensuring ample supply of GMP grade POLB 001 for use in its upcoming LPS human challenge clinical trial, due to commence in June 2022, and for use in investigating POLB 001 as a treatment for other disease indications.
POLB 001 has potential therapeutic applications beyond severe influenza, due to its mode of action of reducing hyperinflammation which is linked with many diseases. This is when harmful inflammation occurs in different areas of the body, such as the heart and lungs, causing organ damage. POLB 001 can block this from happening. The Company holds the worldwide rights to POLB 001 for all uses in humans and as such, is in a position to expand its IP around this asset to cover new disease areas which greatly increases the value of the program for partnering purposes. Following receipt of the results from the upcoming bacterial lipopolysaccharide (LPS) human challenge trial, the Company aims to rapidly monetise POLB 001 by partnering or out licensing the product to pharma / biotech for further development and commercialization.
The GMP manufacturing of the product began in late 2021 to ensure that sufficient grade and quantities of the product is available for use in the forthcoming human challenge trial which is due to commence in June 2022, with first results expected before the end of the year. The Company now has a validated manufacturing process for the development of the product for use in its clinical development for multiple disease areas.
The Company signed the Clinical Trial Agreement with the Centre for Human Drug Research (CHDR) in March 2022 for the upcoming LPS human challenge study. As part of the study, which is being completed in line with the Company’s capital light approach, researchers will stimulate healthy volunteers’ immune systems with LPS which triggers a robust immune response acting as a simulant for the hyperinflammatory effects associated with severe influenza infections, as well as other diseases. The study will provide key human data on the efficacy of POLB 001 in dampening the immune response in otherwise healthy volunteers.
Jeremy Skillington, PhD, CEO of Poolbeg Pharma said: “Preparations for the upcoming clinical trial of our lead asset, POLB 001, are progressing well and we are delighted to have executed a GMP manufacturing contract ensuring ample supply of POLB 001 for use in its clinical development for severe influenza and beyond.
With a mode of action which reduces the body’s hyperinflammatory response, POLB 001 has the potential to address several disease indications beyond severe influenza, and with our exclusive license for all human uses this could provide Poolbeg with the opportunity to greatly increase the value of the program for partnering and monetisation of POLB 001 to pharma or biotech companies.”
Note: Good Manufacturing Practice (GMP) is the regulatory code of standards that a medicine’s manufacturer must meet in its production processes to enable administration to humans.
– Ends –
Enquiries
Poolbeg Pharma Plc Jeremy Skillington, CEO Ian O’Connell, CFO
|
+44 (0) 207 183 1499 |
finnCap Ltd (Nominated Adviser & Joint Broker) Geoff Nash, James Thompson, Charlie Beeson
|
+44 (0) 207 220 0500 |
Arden Partners PLC (Joint Broker) John Llewellyn-Lloyd, Louisa Waddell
|
+44 (0) 207 614 5900 |
J&E Davy (Joint Broker) Anthony Farrell, Niall Gilchrist
|
+353 (0) 1 679 6363 |
Instinctif Partners Melanie Toyne Sewell, Rozi Morris, Tim Field
|
+44 (0) 20 7457 2020 poolbeg@instinctif.com |